Application of gamma-mangostin in preparation of anti-Ebola virus medicine
Through gamma-reverse twistonin, targeting the binding interface between Ebola virus VP30 protein and NP protein, inhibiting Ebola virus RNA synthesis, solving the problem that the existing technology cannot effectively inhibit Ebola virus transcription and replication, and achieving the Ebola virus Effective inhibition of Bola virus provides new anti-Ebola virus drugs.
Patent Information
- Application Number
- CN202310561315.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-18
- Publication Date
- 2024-11-22
AI Technical Summary
There are currently no effective anti-Ebola virus drugs, and the existing technology cannot effectively inhibit the transcription and replication of Ebola virus, resulting in high mortality rate and public health hazards of Ebola virus disease.
Using γ-reverse twistonin as an active ingredient, targets the binding interface between Ebola virus VP30 protein and NP protein, inhibits the RNA synthesis and genomic transcription of Ebola virus, and develops a drug combination against Ebola virus The pH value of the substance is 8.5 to 9.
In the experiment, γ-repellozoin significantly inhibited the growth and reproduction of Ebola virus. The half-inhibiting concentration EC50 was 3.15μM, and the half-inhibiting concentration IC50 was 8.15μM, and there was no obvious cytotoxicity within the effective concentration range. New anti-Ebola virus treatment methods.
Smart Images

Figure CN118986957A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medicines, and particularly relates to application of gamma-mangostin in the preparation of anti-Ebola virus drugs. Background Art
[0002] Ebola virus is a highly pathogenic and lethal virus that causes Ebola hemorrhagic fever. It is a virus belonging to the Filoviridae family. Ebola virus is transmitted to humans through wild animals and spreads between humans, causing Ebola virus disease (EVD) with Ebola hemorrhagic fever. Symptoms include: fever, headache, abdominal pain, severe weakness and fatigue, diarrhea, bloody stools, internal and external bleeding, multiple organ failure, and even death. Since the Ebola virus was first discovered in Africa in 1976, it has broken out in various regions of the world. Each outbreak is often accompanied by a mortality rate of 25%-90%, causing great harm to global human public health, social security, and economic trade. There is currently no specific drug against Ebola virus, and supportive therapy is mainly used clinically to improve survival rates.
[0003] Ebola virus is a single-stranded negative-strand RNA virus, and its genome encodes seven structural proteins and one non-structural protein. The gene sequence is: 3' end-NP-VP35-VP40-GP-VP30-VP24-L-5' end. The VP30, NP, VP35, and L proteins of Ebola virus form a large complex, which is responsible for the RNA synthesis of Ebola virus. Research results have shown that the VP30 protein of Ebola virus is involved in the RNA transcription and replication of Ebola virus, and it is also found that VP30 can directly interact with NP to regulate RNA synthesis. The high-resolution complex crystal structure of VP30 and NP-bound key peptide segments was analyzed by X-ray diffraction crystallography. Analysis of the crystal structure of the complex revealed that VP30 binds to the NP-bound peptide through a specific "molecular pocket", and this binding interface is a potential anti-Ebola virus drug target.
[0004] γ-Mangostin, or Gamma-Mangostin, is a natural product purified from the fruit shell of the medicinal plant mangosteen. It is a competitive 5-HT2A receptor antagonist. It is a transthyretin fibrillation inhibitor, binds to the thyroxine binding site and stabilizes the TTR tetramer, and has the effects of anti-hypertension and prevention of colon cancer. At present, there are no related patent reports on γ-mangostin, nor its application in the prevention or treatment of Ebola virus disease. Summary of the invention
[0005] In order to solve the deficiencies of the prior art, the object of the present invention is to provide the use of γ-mangostin in the preparation of anti-Ebola virus drugs.
[0006] The molecular formula of γ-mangostin is C 23 H 24 O6, molecular weight is 396.43, the structural formula is as follows:
[0007]
[0008] The invention provides application of gamma-mangostin in preparing anti-Ebola virus drugs.
[0009] Furthermore, the γ-mangostin inhibits the transcription and / or replication of the Ebola virus.
[0010] Furthermore, the γ-mangostin targets the binding interface between the Ebola virus VP30 protein and the NP protein, inhibiting the synthesis of Ebola virus RNA.
[0011] The present invention also provides an anti-Ebola virus pharmaceutical composition, the active ingredient of which includes gamma-mangostin, and the pH value of the pharmaceutical composition is 8.5-9.
[0012] The present invention also provides the use of gamma-mangostin in preparing a drug that targets the binding interface between the Ebola virus VP30 protein and the NP protein.
[0013] Furthermore, the targeting effect is a targeted inhibition effect.
[0014] The present invention also provides a drug for targeted inhibition of the binding between Ebola virus VP30 protein and NP protein, wherein the active ingredient includes gamma-mangostin, and the pH value of the drug is 8.5-9.
[0015] The present invention has the following beneficial effects:
[0016] The present invention discovers the activity of γ-mangostin against Ebola virus. Specific experiments show that γ-mangostin can effectively inhibit Ebola virus in Huh7-4P cells of Ebola virus model minigenome system (Minigenome). γ-mangostin is used to inhibit the transcription and replication of Ebola virus genome, inhibit the growth or reproduction of Ebola virus, and inhibit the synthesis of corresponding genome in Huh7-4P cells of Ebola minigenome system (Minigenome). Its half inhibition concentration EC 50 γ-mangostin can target the "active pocket" at the binding interface between Ebola virus VP30 protein and NP protein, and exhibits good inhibitory activity in fluorescence polarization experiments. Its half inhibitory concentration IC 50The concentration of γ-mangostin is 8.15 μM. At the same time, γ-mangostin has no obvious cytotoxicity within the effective concentration range. Therefore, γ-mangostin can be used to prepare anti-Ebola virus drugs, which expands the scope of use of γ-mangostin, especially in the case of severe shortage of anti-Ebola virus specific drugs, and provides new drugs and new treatment methods for inhibiting Ebola virus disease caused by Ebola virus. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 The inhibition rate curve of the fluorescence polarization method of γ-mangostin in Example 1 of the present invention at different concentrations of the Ebola virus VP30 protein and the NP interaction interface is shown in the figure, wherein the abscissa represents the γ-mangostin drug concentration, the ordinate represents the polarized fluorescence value, and the half inhibition concentration IC of γ-mangostin for inhibiting the Ebola virus VP30 protein is calculated according to the inhibition rate 50 value;
[0018] Figure 2 This is a graph showing the inhibition rate of γ-mangostin at different concentrations in Example 2 of the present invention in inhibiting the Ebola virus minigenome system Huh7-4P cells, wherein the abscissa represents the γ-mangostin drug concentration, the ordinate represents the fluorescence value of the luciferase reporter gene of the minigenome system with the solvent group as the control, and the half inhibition concentration IC of γ-mangostin to inhibit the Ebola virus minigenome system is obtained 50 value;
[0019] Figure 3 The cytotoxicity curve of γ-mangostin at different concentrations on the Ebola virus minigenome system Huh7-4P cells in Example 3 of the present invention is shown, wherein the abscissa represents the γ-mangostin drug concentration, the ordinate represents the survival rate of Huh7-4P cells with the solvent group as the control, and the half lethal concentration CC of γ-mangostin on cells is obtained. 50 value;
[0020] Figure 4 This is a graph showing the affinity determination of γ-mangostin with the Ebola virus VP30 protein at different concentrations in Example 4 of the present invention, wherein the abscissa represents the binding and dissociation time of the VP30 protein with γ-mangostin, and the ordinate represents the binding response value of γ-mangostin with the VP30 protein with the solvent group as the control, and the affinity constant K of γ-mangostin with the Ebola VP30 protein is obtained. D value;
[0021] Figure 5This is a curve diagram of the change in the Tm value of the VP30 protein after γ-mangostin binds to the Ebola virus VP30 protein under different pH conditions in Example 5 of the present invention, wherein the abscissa represents different pH environments, the ordinate represents the Tm value of the VP30 protein with the solvent group as the control, and the binding ability of γ-mangostin to the Ebola VP30 protein under different pH conditions is judged based on the change in the Tm value before and after the binding. DETAILED DESCRIPTION
[0022] In order to better understand the content of the present invention, the content of the present invention is further described below in conjunction with the accompanying drawings and specific implementation methods, but the protection content of the present invention is not limited to the following examples. Unless otherwise defined, the technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention. The terms used in the specification of the present invention are for the purpose of describing specific embodiments and are not limited to the present invention.
[0023] The following examples mainly evaluate the anti-Ebola virus activity of γ-mangostin by constructing a fluorescence polarization method for the interaction between Ebola virus VP30 protein and NP binding peptide and an Ebola minigenome system (Minigenome), and confirm that γ-mangostin has the effect of resisting Ebola genome transcription and replication, and inhibiting Ebola RNA synthesis, and provide a use of γ-mangostin in the preparation of anti-Ebola virus drugs.
[0024] The Ebola minigenome system (Minigenome) Huh7-4P cells used in the present invention were kindly donated by Professor Zhong Jin of Shanghai Pasteur Institute.
[0025] In the present invention, stably overexpressing Ebola VP30 110-272 The plasmid of the protein was constructed and preserved by our unit. 110-272 The protein sample was expressed and purified by the inventors with a purity of >95%.
[0026] The FITC-eNP fluorescent polypeptide used in the examples of the present invention was synthesized by Nanjing GenScript Biotechnology Co., Ltd. with a purity of >95%.
[0027] The cell growth culture medium used in the embodiment of the present invention is composed of: DMEM basal culture medium, to which 10% of fetal bovine serum, 1% of ampicillin / streptomycin and 0.1 mg / mL hygromycin are added. The culture medium is stored at 4°C and preheated in a 37°C water bath before use.
[0028] The γ-mangostin used in the examples of the present invention was purchased from Shanghai Taosu Biochemical Technology Co., Ltd., with a purity of >99%.
[0029] The dual luciferase detection kit used in the examples of the present invention was purchased from Shanghai Bio-Tech Biotechnology Co., Ltd., and includes a cell lysate and a luciferase reaction substrate.
[0030] Example 1
[0031] Detection of the inhibitory activity of γ-mangostin on the "active pocket" of the Ebola VP30 protein-NP binding interface (e.g. Figure 1 ).
[0032] 1. Establishment of Ebola virus VP30 110-272 Fluorescence polarization method for protein-NP interaction:
[0033] 1) VP30 110-272 Determination of protein concentration: FITC-eNP fluorescent polypeptide was dissolved in a buffer solution, the buffer composition of which included: 10mM HEPES pH 7.0, 150mM NaCl, 2mM DTT, so that the concentration was 1μM. VP30 110-272 The protein was diluted with the same buffer to an initial concentration of 240 μM, and the protein was diluted 2.5 times. The total volume of the reaction system was 100 μL. First, 50 μL of VP30 of different concentrations was added. 110-272 The protein solution was added to a 96-well blackboard, with 3 replicate wells for each concentration, for a total of 10 drug gradients, to a final concentration of (120, 48, 19.2, 7.68, 3.07, 1.23, 0.49, 0.20, 0.079, 0.031 μM); then, 50 μL of 1 μM FITC-eNP fluorescent peptide solution was added to the system to a final concentration of 500 nM. Oscillate and mix for 5 seconds, incubate at room temperature for 30 minutes, and read the polarized fluorescence value on the microplate reader. The instrument settings are: excitation wavelength 485 nm, emission wavelength 528 nm, bandpass 20 nm, automatic gain, reading height 8.5 mm, G factor 1.26. Determine VP30 by concentration titration 110-272 Protein concentration.
[0034] 2) Determination of the optimal concentration of FITC-eNP fluorescent polypeptide: FITC-eNP fluorescent polypeptide was dissolved in a buffer solution, the buffer composition of which included: 10 mM HEPES pH 7.0, 150 mM NaCl, 2 mM DTT, to a concentration of 1 μM. 110-272 Protein concentration range, set different concentrations of FITC-eNP fluorescent peptide to determine the optimal concentration. Use different concentrations of FITC-eNP fluorescent peptide to titrate different concentrations of VP30 110-272 Protein concentration. The total volume of the reaction system was 100 μL. First, 50 μL of VP30 of different concentrations was added. 110-272The protein solution was added to a 96-well blackboard, and 3 replicate wells were set for each concentration, with a total of 10 drug gradients, so that the final concentration was (120, 48, 19.2, 7.68, 3.07, 1.23, 0.49, 0.20, 0.079, 0.031 μM); then, 50 μL of FITC-eNP fluorescent polypeptide solution of different concentrations was added to the system, and 3 replicate wells were set for each concentration, with a total of 5 drug gradients, so that the final concentration was (500, 400, 300, 200, 100, 50 nM). Oscillate and mix for 5 seconds, incubate at room temperature for 30 minutes, and read the polarized fluorescence value on the microplate reader. The instrument settings are: excitation wavelength of 485 nm, emission wavelength of 528 nm, bandpass of 20 nm, automatic gain, reading height of 8.5 mm, and G factor of 1.26. The optimal concentration of FITC-eNP fluorescent polypeptide was determined by concentration titration.
[0035] 3) Determine the IC of the established method 50 :The optimum VP30 determined by the above concentration titration method 110-272 Protein concentration range and FITC-eNP fluorescent peptide concentration, method validation and calculation of IC 50 The total volume of the reaction system was 100 μL. First, 50 μL of VP30 of different concentrations was added. 110-272 The protein solution was added to a 96-well black board, and 3 replicate wells were set for each concentration, with a total of 10 drug gradients, so that the final concentration was (120, 48, 19.2, 7.68, 3.07, 1.23, 0.49, 0.20, 0.079, 0.031 μM); then, 50 μL of FITC-eNP fluorescent peptide solution with a concentration of 0.6 μM was added to the system to make the final concentration 300 nM. Oscillate and mix for 5 seconds, incubate at room temperature for 30 minutes, and read the polarized fluorescence value on the microplate reader. The instrument settings are: excitation wavelength of 485 nm, emission wavelength of 528 nm, bandpass of 20 nm, automatic gain, reading height of 8.5 mm, and G factor of 1.26.
[0036] 2. Determination of the half inhibitory concentration (IC) of γ-mangostin by fluorescence polarization 50 ):
[0037] The optimal VP30 was determined according to the fluorescence polarization method established above. 110-272 Protein concentration and FITC-eNP fluorescent peptide concentration, perform method validation and calculate IC 50 The total volume of the reaction system was 100 μL. First, 50 μL of 15.36 μM VP30 was added. 110-272The protein solution was added to a 96-well black board, and then 1 μL of different concentrations of γ-mangostin (solvent was DMSO) was added to the system, keeping the proportion of DMSO in all concentration wells the same. The initial drug concentration was set to 200 μM, with a total of 12 drug gradients, and 3 replicates for each concentration, so that the final drug concentration was 200, 100, 50, 25, 12.5, 6.25, 3.12, 1.56, 0.78, 0.39, 0.195, 0.098 μM; the drug and protein were incubated for 30 minutes. Finally, 50 μL of FITC-eNP fluorescent peptide solution with a concentration of 0.6 μM was added to the system to a final concentration of 300 nM. Oscillate and mix for 5 seconds, incubate at room temperature for 60 minutes, and read the polarized fluorescence value on the microplate reader. The instrument settings were: excitation wavelength 485 nm, emission wavelength 528 nm, bandpass 20 nm, automatic gain, reading height 8.5 mm, G factor 1.26.
[0038] 3. Results:
[0039] 1) VP30 110-272 Determination of protein concentration: According to the fluorescence polarization signal measured by the microplate reader, the inhibition curve was fitted using Prism8.0 software. 50 Value, determine VP30 110-272 The protein concentration was 7.68 μM.
[0040] 2) Determination of FITC-eNP fluorescent peptide concentration: According to the fluorescence polarization signal measured by the microplate reader, the inhibition curve was fitted using Prism8.0 software, and the trend of the fitting curve at different concentrations and IC 50 The optimal FITC-eNP fluorescent polypeptide concentration was determined to be 300 nM.
[0041] 3) Determine the IC of the established method 50 :According to the fluorescence polarization signal measured by the microplate reader, the fluorescence polarization method established above was verified, and the inhibition curve was fitted using Prism8.0 software. The IC 50 The value is 2.92μM.
[0042] 4) The half inhibitory concentration (IC) of γ-mangostin 50 ): The inhibition rate was calculated based on the corresponding relationship between the fluorescence value and the drug concentration. The curve was drawn using Prism 8.0 software to calculate the half inhibitory concentration IC of γ-mangostin. 50 It is 8.15μM.
[0043] Example 2
[0044] Detection of the antiviral activity of γ-mangostin on the Ebola minigenome system (Minigenome) Figure 2 ).
[0045] 1. Methods:
[0046] 1) Minigenome system (Minigenome) antiviral activity test: The antiviral activity test was carried out on the Ebola virus minigenome system (Minigenome), and the antiviral activity of γ-mangostin was evaluated using the internationally recognized anti-Ebola virus evaluation system. Huh7-4P cells of the Ebola minigenome system (Minigenome) in the logarithmic growth phase were taken and 1*10 4 Each well was evenly plated in a 96-well cell plate, with each well containing 100 μL of cell culture medium. The cells were cultured in a 37°C cell culture incubator for 24 hours.
[0047] 2) The drug was dissolved in DMSO to form a high concentration stock solution, and then diluted to 400 μM with DMEM medium containing 2% fetal bovine serum in total volume, and diluted 2 times, with a total of 12 concentration gradients, and the total concentrations were 200, 100, 50, 25, 12.5, 6.25, 3.12, 1.56, 0.78, 0.39, 0.195, and 0.098 μM. 100 μL of drug was added to each well, and the total volume of the system was 200 μL. There were 3 replicates for each concentration, and an equal proportion of DMSO solvent was added to the control group, and an equal volume of DMEM complete medium was added to the blank group. After adding the drug, the cells were cultured in a cell culture incubator at 37°C for 24 hours. The 96-well plate was removed, and the cell culture supernatant was aspirated and discarded with a pipette. The cells were washed once with 100 μL / well sterile PBS (pH 7.4), and 100 μL of 1X cell lysis buffer was added to each well, and the cells were shaken and lysed at room temperature for 15 minutes. Transfer 50 μL / well of the lysate supernatant to a 96-well white ELISA plate, add an equal volume of diluted luciferase substrate according to the instructions of the dual luciferase assay kit, and immediately use an ELISA instrument to detect the fluorescence value. According to the fluorescence value, determine the activity of γ-mangostin in inhibiting viral genome synthesis. Calculate the inhibition rate based on the corresponding relationship between the fluorescence value and the drug concentration, draw a curve, and calculate the half-maximal inhibitory concentration IC of γ-mangostin. 50 .
[0048] 2. Results:
[0049] The DMSO solvent group was used as the blank control, and the inhibition rate of the drug treatment group was calculated based on the fluorescence value. Then, according to the inhibition rate of the drug treatment groups with different concentrations, the drug inhibition rate curve was fitted using Prism8.0 software, and the half inhibition concentration IC of γ-mangostin for inhibiting Ebola virus RNA synthesis was calculated. 50 It is 3.15μM.
[0050] Example 3
[0051] Cytotoxicity assay of γ-mangostin (e.g. Figure 3 ).
[0052] 1. Methods:
[0053] 1) Cell inoculation: Huh7-4P cells in the logarithmic growth phase, adjust the cell density to 1×10 4 100 μL / well was inoculated into 96-well plates and cultured overnight.
[0054] 2) Drug concentration design: Huh7-4P cells: Before administration, the drug was diluted to 200 μM with DMEM medium containing 2% fetal bovine serum in total volume, and 100 μL of the diluted drug was taken in each well and added to the Huh7-4P cells in the 96-well plate in 1), with a final volume of 200 μL in each well, 2-fold dilution, a total of 9 concentration gradients, and total concentrations of 100, 50, 25, 12.5, 6.25, 3.12, 1.56, 0.78, and 0.39 μM, respectively; 3 replicate wells were set for each drug concentration, and the DMSO solvent treatment group was used as the blank control.
[0055] 3) Detection of absorbance: After 48 hours of incubation in the incubator, add 10 μL of CCK-8 working solution to each well and continue incubation in the incubator for 3 hours. Measure the absorbance at 450 nm using an enzyme-labeled instrument.
[0056] 4) Based on the measured OD values, the survival rates of Huh7-4P cells under the action of drugs at various concentrations were calculated compared with the control group.
[0057] 2. Results:
[0058] γ-mangostin has an inhibitory effect on Huh7-4P cells ( Figure 3 ) No obvious toxic effect, CC 50 >200μM.
[0059] Example 4
[0060] γ-Mangostin and Ebola virus VP30 110-272 Protein affinity determination (eg Figure 4 ).
[0061] 1. Surface Plasmon Resonance (SPR):
[0062] Surface plasmon resonance (SPR) determination of potential small molecules and VP30 110-272 Protein-protein binding capacity and kinetics, using Plexera PlexArray TM HT instrument was used for the determination.
[0063] (1) Spotting: Before the binding experiment, small molecule compounds of different concentrations are marked on the 3D optical cross-linking chip according to the SOP. Each small molecule sample is spotted with two different concentrations (5mM and 10mM), and the solvent is DMSO. Spot the sample on the chip surface, and be careful to avoid light. After spotting, place the chip in a vacuum drying oven to dry for 30 minutes. The dried chip is placed in the photocross-linker for photocross-linking reaction for 15 minutes. The cross-linked chip is washed with DMF, C2H5OH and water on a shaker for 15 minutes, and then blown dry with a nitrogen blower. Fix it with a cover and record the sample position.
[0064] (2) SPR machine: PBS was used as binding buffer and 0.01M Gly-HCl pH 2.0 as regeneration buffer. Small molecule inhibitors were immobilized on the chip as the stationary phase, and VP30 protein was used as the mobile phase, which was diluted with PBS to different concentrations, such as 10, 5, 2.5, 12.5, 0.625, and 0.3125 μM. All experimental operations were performed in accordance with the instrument protocol. The measurement method was set as: 300 s baseline, 300 s binding, and 300 s dissociation. For each baseline step throughout the experiment, fresh PBS buffer was used. The entire data collection process was automated, including recording continuous measurement cycles. Each independent analysis cycle included baseline, binding, dissociation, regeneration, and return to baseline. The data was processed using the Plexera analysis program. The data collected by the instrument were plotted using GraphPadPrism 8.0.2 according to the corresponding relationship between time and intensity, which is the association dissociation response curve. In addition, the affinity constant (K D ).
[0065] 2. Results: Figure 3 As shown;
[0066] When the program is completed, the SPR sensor graph shows that the affinity constant (K D ) is 22.1μM.
[0067] Example 5
[0068] γ-Mangostin and Ebola virus VP30 110-272 Thermal drift experiments of proteins (such as Figure 5 ).
[0069] 1. Methods:
[0070] According to the final protein concentration of 0.1-1 mg / mL, the protein was first diluted to 13 μM with a universal buffer of 150 mM NaCl, 20 mM Tris, pH 7.5, and γ-mangostin was diluted to 15.6 μM with DMSO. The drug concentration should be 1.2 times the protein concentration.110-272 The protein was placed in different pH buffers (pH 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5), and then 10 μL of VP30 in different pH buffers was taken. 110-272 The protein was mixed with 10 μL of drug or an equal volume of DMSO in the corresponding pH buffer, and the final protein concentration was adjusted to 6.5 μM and the final drug concentration was 7.8 μM. Two groups of controls were set up in this experiment, one group without protein, i.e., drug and different pH buffers; and one group without compound, i.e., protein and DMSO in different pH buffers. After incubation for 10 minutes, 1 μL of SYPRO Orange solution was added to each sample well or blank well and incubated for another 30 minutes. Three replicates were set for all samples and controls. All samples and controls were placed in PCR eight-tube strips and heated from 25°C to 95°C at a rate of 1°C / min on the Bio-Rad CFX1000 instrument, and the fluorescence signal was monitored using ROX as the fluorescence channel.
[0071] 2. Results:
[0072] In thermal drift experiments, SYPRO Orange, a fluorescent dye that binds to hydrophobic residues, was used to monitor the dynamics of VP30 as the temperature increased. 110-272 Denaturation of the drug and calculation of melting temperature (Tm). When the drug binds to the protein, the stability of the protein may change (i.e., Tm shifts). For γ-mangostin, 6.5 μM VP30 at a 1:1.2 molar ratio was used at six different pH conditions. 110-272 Thermal shift assay was performed with a mixture of VP30 and 7.8 μM γ-mangostin, and a protein sample without γ-mangostin was used as a control. 110-272 and VP30 110-272 The mixtures with γ-mangostin showed the highest thermal stability at pH 7.5. At pH 8.5 and 9, the mixtures with VP30 110-272 Compared with VP30 110-272 Binding to γ-mangostin increases stability. Experiments show that γ-mangostin binds to the target protein VP30 at pH 8.5 and 9. 110-272 Has the best binding ability.
[0073] The above description is only a specific implementation mode of the present invention, not all implementation modes. Any equivalent changes made to the technical solution of the present invention by ordinary technicians in this field after reading the specification of the present invention are covered by the claims of the present invention.
Claims
1. Application of γ-mangostin in the preparation of anti-Ebola virus drugs.
2. The use according to claim 1, It is characterized in that The γ-mangostin inhibits the transcription and / or replication of Ebola virus.
3. The use according to claim 1, It is characterized in that The gamma-mangostin targets and acts on the binding interface between the Ebola virus VP30 protein and the NP protein, thereby inhibiting the synthesis of the Ebola virus RNA.
4. A pharmaceutical composition for resisting Ebola virus, It is characterized in that The active ingredient of the pharmaceutical composition includes gamma-mangostin, and the pH value of the pharmaceutical composition is 8.5-9.
5. Application of γ-mangostin in the preparation of drugs targeting the binding interface between Ebola virus VP30 protein and NP protein.
6. The use according to claim 5, It is characterized in that The targeting effect is a targeted inhibition effect.
7. A drug that targets and inhibits the binding of Ebola virus VP30 protein to NP protein. It is characterized in that The active ingredient of the medicine includes gamma-mangostin, and the pH value of the medicine is 8.5-9.
